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Objectives: Remote ischaemic preconditioning (RIPC) has two time windows for organ 
protection: acute and delayed. Previous studies have mainly focused on the acute time 
window to evaluate organ protection by RIPC. We evaluated myocardial and renal protection 
by delayed RIPC in adult patients undergoing cardiac surgery. 
Methods: A total of 160 adult patients undergoing cardiac surgery with cardiopulmonary 
bypass were randomized to receive either delayed RIPC (four cycles of 5 min of ischaemia 
followed by 5 min of reperfusion by inflation to 200 mmHg and deflation of a blood pressure 
cuff on the upper arm) or the control treatment 24-48 h before surgery. The primary endpoint 
was post-operative troponin I levels serially measured for 72 h. 
Results: Post-operative troponin I values did not differ between the delayed RIPC and the 
control group (area under the curve for the serum troponin I at 72 h; median (IQR), 743.45 
(276.36 – 1464.06) h.ng/mL and 530.78 (264.58 – 1232.61) h.ng/mL, respectively; p=0.414). 
Furthermore, no significant differences between groups were seen in the secondary endpoints 
including acute kidney injury and composite complications. 





What is already known about this subject? 
Remote ischaemic preconditioning (RIPC) has two time windows for organ protection: acute 
and delayed. Previous studies have mainly focused on the acute time window to evaluate 
organ protection by RIPC. However, clinical trials investigating the benefits of delayed RIPC 
are lacking. 
 
What does this study add? 
In this randomized controlled clinical trial, patients undergoing cardiac surgery with 
cardiopulmonary bypass were randomized to receive either delayed RIPC or the control 
treatment 24-48 h before surgery. There were no significant differences in post-operative 
troponin I values between groups. Furthermore, no significant differences between groups 
were seen in the secondary endpoints including acute kidney injury and composite 
complications. 
. 
How might this impact on clinical practice? 
The study findings suggest that delayed RIPC may not provide cardioprotective effects in 
patients undergoing cardiac surgery. Further studies are needed to evaluate the systemic 





Remote ischaemic preconditioning (RIPC) by brief episodes of limb ischaemia and 
reperfusion provides protection against acute ischaemia-reperfusion injury in distal organs.[1, 
2] RIPC is a non-invasive and powerful therapeutic intervention for inducing organ protection 
and is associated with a reduced risk of peri-operative myocardial injury after cardiac 
surgery.[3-7] Additionally, it provides a protective effect to other distal organs, such as the 
kidneys and lungs.[4, 8-10]  
The protective effect of preconditioning has a biphasic pattern; acute protective 
effects wane after a few hours, but a delayed second window of protection occurs after 12-24 
h.[11, 12] The acute effects rely on the activation of existing signaling molecules, whereas the 
delayed effects are achieved by increased expression of protective proteins.[11, 12] Delayed 
phase preconditioning provides sustained protection from myocardial infarction, as well as 
protective potential against myocardial stunning, arrhythmia, and endothelial dysfunction.[11] 
In contrary to previous studies that demonstrated cardioprotective effect of RIPC,[1, 
2] recent large clinical trials in cardiac surgery have failed to show clinical benefit by acute 
RIPC.[13, 14] Although we do not know which factors interfere with the protective effect of 
acute RIPC in cardiac surgery, the different time window of ischaemia in delayed RIPC may 
have the advantage to bypass the unknown interfering factors. However, unlike acute RIPC, 
clinical trials investigating the benefits of delayed RIPC are lacking. We hypothesized that 
delayed RIPC has clinically significant myocardial protective effects. The aim of the study 
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was to investigate whether delayed RIPC decreased myocardial and renal injury in patients 




Ethical approval for this study (1211-041-441) was provided by the institutional review board 
of Seoul National University Hospital. The study protocol was registered at ClinicalTrials.gov 
(NCT01903161). Written informed consent was obtained from all patients enrolled in the 
study. There were no important changes to the methods or outcomes after trial 
commencement. Patients aged 18 to 80 years and scheduled for elective cardiac surgery with 
CPB were included. Exclusion criteria were as follows: left ventricular ejection fraction < 
30%, pre-operative administration of vasopressors or inotropes, chronic liver disease with 
Child-Pugh class C, chronic kidney disease requiring dialysis, diabetes, peripheral vascular 
disease affecting the upper limbs, descending thoracic aortic surgery, and rare surgeries, such 
as cardiac transplantation or correction of congenital anomalies. A total of 160 patients were 
included in the study from May 2013 to January 2015. 
Randomization 
This was a single-center, parallel-group randomized study conducted at the Seoul National 
University Hospital, a tertiary hospital in Seoul, Korea. Eligible patients were randomly 
allocated to either the delayed RIPC group or the control group using a computer-generated 
list. The randomization sequence was created with a 1:1 allocation using a random block size 
of 4. The random list was generated by a statistician who was not involved in the study and 
who was blinded to all patients, medical personnel, and investigators. 
Remote ischaemic preconditioning 
An independent nurse performed RIPC 24 to 48 h prior to surgery. RIPC consisted of four 
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cycles of 5 min of ischaemia, which was induced by a blood pressure cuff in the upper arm 
inflated to 200 mmHg, followed by 5 min of reperfusion, during which the cuff was deflated. 
In the control group, the same blood pressure cuff was placed around the upper arm, but the 
cuff was inflated to 10 mmHg and ischaemic preconditioning was not induced. 
Anaesthesia and cardiopulmonary bypass techniques 
All patients received standard peri-operative care. Routine monitoring included a bispectral 
index, cerebral oximetry, a pulmonary artery catheter, and transoesophageal echocardiography. 
Anaesthesia was induced with intravenous midazolam 0.15 mg/kg, sufentanil 1 μg/kg, and 
vecuronium 0.15 mg/kg, and was maintained with target controlled infusions of remifentanil 
6-12 ng/mL and propofol 1.5-2.5 µg/mL, maintaining bispectral index values between 40 and 
60. 
Study patients underwent cardiac surgery using a non-pulsatile CPB technique with a 
membrane oxygenator and cardiotomy suction. Cardiac protection was achieved using 
antegrade or retrograde cold-blood cardioplegia. Heparin was administered before CPB and 
was reversed by protamine after discontinuing CPB. The target activated clotting times during 
surgery were more than 500 s. At the end of surgery, patients were transferred to the intensive 
care unit. Intensive care unit management was provided by attending physicians and 
standardized for all patients according to the routine protocol of our institution. 
Study outcomes 
The primary endpoint was serum troponin I, measured at 1, 6, 12, 24, 48, and 72 h post-
operatively. Serum troponin I has previously been used as a marker of peri-operative 
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myocardial injury after cardiac surgery.[3, 4, 15] The secondary endpoints included post-
operative serum creatinine levels, acute kidney injury (AKI), defined by the Acute Kidney 
Injury Network (AKIN) staging system,[16] and composite complications. In the AKIN 
criteria, serum creatinine criteria was used and the pre-operative creatinine levels were used 
as baseline levels. Composite complications included in-hospital death, myocardial infarction, 
new onset atrial fibrillation, stroke, AKI, respiratory failure, persistent cardiogenic shock, and 
gastrointestinal complications.[17] Myocardial infarction was defined as an elevation of 
cardiac biomarker values (> 10× 99th percentile upper reference limit) in patients with normal 
baseline troponin values (< 99th percentile upper reference limit). Additionally, new 
pathological Q waves or new left bundle branch block, or imaging evidence of new loss of 
viable myocardium or new regional wall motion abnormality, was required.[18] Respiratory 
failure was defined as the need for post-operative mechanical ventilation for > 72 h. Persistent 
cardiogenic shock was defined as use of inotropic agents, vasopressors, or a mechanical assist 
device for more than 72 h. Gastrointestinal complications were defined as gastrointestinal 
bleeding requiring transfusion, pancreatitis requiring nasogastric suction, cholecystitis 
requiring drainage, or mesenteric ischaemia requiring exploration. Additional secondary end 
points were cardiovascular mortality, ventricular arrhythmia, renal replacement therapy, 
mechanical ventilation time, intensive care unit and hospital length of stay, use of intraaortic 





In the study by Hong et al.,[15] the area under the curve (AUC) of post-operative troponin I 
was 69.4 ± 74.5 h·ng/mL. Presuming that the difference of 50% in troponin I AUC was 
clinically significant, 74 patients were required in each group to detect a difference, with a 
type I error of 0.05 and a power of 0.8. To allow for dropouts, 80 patients were recruited for 
each group. Continuous variables of patient demographics and group characteristics were 
compared using the Student’s t-test or the Mann–Whitney U test after testing for normality. 
Categorical variables were analyzed using the χ2 test or Fisher’s exact test, where appropriate. 
Changes in serum troponin I and creatinine over time were analyzed using repeated measures 
analysis of variance (ANOVA).. The AUC was determined using the standard trapezoidal 
method. A p<0.05 was regarded as statistically significant. Adjusted p values were calculated 
using Hochberg method in order to correct for multiple testing. Data were analyzed using 





Of the 232 patients screened, 72 were excluded; 16 for left ventricular ejection fraction < 30%, 
18 for renal impairment requiring renal replacement therapy, 19 for diabetes, 9 for pre-
operative administration of vasopressors or inotropes, 8 for peripheral vascular disease, and 2 
for declining to participate (Fig. 1). One hundred sixty randomized patients received the 
allocated interventions and were included in the final analysis. Demographic data for the 
patients are shown in Table 1. Time from RIPC or sham to aorta cross clamp and reperfusion, 
aortic cross-clamp time, duration of CPB, and surgery were comparable between groups 
(Table 2). 
Serum troponin I 
Serum troponin I levels significantly increased after surgery and peaked 1 h post-operatively 
(Fig. 2). Changes in serum troponin I were not significantly different between groups 
(p=0.662, Fig. 2). Moreover, the total 72 h AUC of troponin I did not differ between the 
delayed RIPC and control groups (median (IQR), 743.45 (276.36 – 1464.06) h.ng/mL vs. 
530.78 (264.58 – 1232.61) h.ng/mL, p=0.414). 
Acute kidney injury 
The incidence of post-operative AKI based on the AKIN staging system was decreased in the 
delayed RIPC group compared to the control group (30.0% vs. 47.5%; RR, 0.632; 95% CI, 
0.421 – 0.948; p=0.023). However, adjusted p value for multiple comparison was not 
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statistically significant (RR, 0.632; 99.8% CI 0.338 – 1.232; p=0.46, Table 3). In both groups, 
most AKIs were categorized as AKIN class 1. The number of patients categorized as AKIN 
class 3, which includes individuals who received renal replacement therapy, was comparable 
between groups (5.0% vs. 5.0%, see Supplementary dada). Changes in serum creatinine were 
not significantly different between groups (p=0.714, Fig. 3). 
Composite complications 
The rate of composite complications was lower in the delayed RIPC group compared to the 
control group (65.0% vs. 81.3%; RR, 0.800; 95% CI, 0.660 – 0.970; p=0.020), but not 
significant when adjusted for multiple comparisons (RR, 0.800; 99.8% CI 0.574 – 1.091; 
adjusted p=0.42, Table 3). In-hospital mortality rate and cardiovascular mortality rate were 
higher in the control group but the difference did not reach statistical significance (Table 3). 
Causes of death included cardiogenic shock (four patients in the control group and one patient 
in the delayed RIPC group), diffuse bleeding of unknown etiology (one patient in the control 
group), and septic shock (one patient in the delayed RIPC group). Incidence of post-operative 
new onset atrial fibrillation, risks of myocardial infarction, respiratory failure, and 
gastrointestinal complications were lower in the delayed RIPC group but the difference did 




In patients undergoing cardiac surgery with CPB, delayed RIPC did not show cardioprotective 
effects as assessed by troponin I levels. Cardiac surgery with CPB can cause global 
myocardial ischaemia-reperfusion injury, the presence of which can be quantified by 
measuring cardiac enzymes and is associated with worse clinical outcomes. RIPC is a non-
invasive, inexpensive, and powerful therapeutic intervention for inducing cardioprotection in 
patients undergoing cardiac surgery; previous studies have shown that RIPC reduces peri-
operative myocardial injury and possibly improves prognosis.[4, 5, 7] However, the clinical 
effects of delayed RIPC have not been adequately studied. Wagner et al. first reported that the 
delayed phase of RIPC could reduce peri-operative myocardial injury in cardiac surgery.[19] 
However, this effect was not evident in the study by Pavione et al., which was performed in 
children undergoing CPB.[20]  
Contrary to our study, previous meta-analyses of clinical trial data on acute RIPC 
showed a myocardial protective effect,[6, 7] which could be due to various possibilities. First, 
acute RIPC may be more effective than delayed RIPC for myocardial protection. In a previous 
animal study, only acute RIPC decreased reperfusion-induced ventricular arrhythmias.[21] 
However, we did not compare early and delayed RIPC in this study. Second, previous acute 
RIPC studies with positive results were mostly performed in patients undergoing coronary 
artery bypass graft or uncomplicated single valve surgery,[4, 6, 15] while in this study, 58 
patients underwent complicated cardiac surgeries such as double or triple valve surgery, and 
aorta cross clamping time was much longer than in previous studies.[3-5] These findings raise 
the possibility that the myocardial protective effects of RIPC might be insufficient in 
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complicated cardiac surgeries with significant myocardial injury.[22]    
The prevalence of AKIN class 1 AKI was less in the delayed RIPC group compared 
to the control group in this study. It is well-known that AKI is frequent after cardiac surgery 
and is associated with morbidity and mortality.[23] Previous meta-analyses reported that there 
is no definitive evidence of renal protection after RIPC.[6, 7] However, several recent studies 
have demonstrated the beneficial role of acute phase RIPC on kidney protection.[8, 10] 
Interestingly, in a meta-analysis investigating RIPC in animal models, delayed RIPC was 
more effective than acute RIPC in reducing serum creatinine after renal ischaemia-reperfusion 
injury (standardized mean difference 2.43; 95% confidence interval, 1.29 – 3.57).[24] In a 
recent study in pigs, delayed RIPC showed significant reduction in renal injury biomarkers 
such as urinary neutrophil gelatinase-associated lipocalin, and kidney injury molecule-1 
compared to acute RIPC.[25] Considering that even a small increase in serum creatinine 
levels is associated with poor outcomes,[23] our study suggests that delayed RIPC might be a 
therapeutic option to attenuate AKI. However, our study was not powered to detect the 
difference in AKI, and the finding should be interpreted with caution. 
It has been demonstrated that RIPC has systemic protective effects on various distal 
organs;[2] however, in our previous clinical trial on 1280 cardiac surgery patients, acute RIPC 
did not decrease composite complications.[17] Recent multicenter trials, The Effect of 
Remote Ischemic Preconditioning on Clinical Outcomes in Patients Undergoing Coronary 
Artery Bypass Graft Surgery (ERICCA) trial[13] and the Remote Ischemic Preconditioning 
for Heart Surgery (RIPHeart) Study,[14] also failed to show a relevant clinical benefits of 
acute RIPC in cardiac surgery. The authors suggested that lack of standardization of 
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perioperative anaesthesia may have affected the efficacy of RIPC. Then, delayed RIPC 24 to 
48 h prior to the cardiac surgery may be more practical in the clinical setting compared with 
the acute RIPC which may be affected by multiple confounders such as propofol during the 
surgery. Also, we hypothesize that delayed RIPC does not result in the transient harmful 
effects of RIPC techniques leading to inflammation and coagulation;[26, 27] if true, this 
suggests that delayed RIPC may be more beneficial in cardiac surgery patients compared with 
acute RIPC. Although not significant after adjustment, the rate of composite complications 
was lower in the delayed RIPC group than in the control group in this study. Similar trends 
were observed for in-hospital mortality, cardiovascular mortality, myocardial infarction and 
new-onset atrial fibrillation. 
The exact mechanisms underlying the organ protective signal transfer from remote 
ischaemic stimuli to distal organs are not yet clear; however, neuronal and humoral 
transmission are widely suggested.[2] Time-dependent transcription and synthesis of 
cardioprotective mediators or neuronal release of a signal molecule may account for the two 
distinct windows of organ protection in RIPC.[2, 12] Unlike acute RIPC, delayed RIPC 
requires the synthesis of new proteins such as nitric oxide synthase, cyclooxygenase-2, aldose 
reductase, and antioxidant enzymes.[11, 12] Through its systemic effects, delayed RIPC may 
provide distal organ protection, such as kidney protection, as suggested in this study. While 
the acute preconditioning effect lasts only 2-3 h, delayed preconditioning has a longer 
duration of protection, ranging from 3-4 days.[11, 12] It is not always easy in cardiac 
surgeries even in elective cases that ischemia-reperfusion injury occur on the exact protective 
time window. It may be one of the reason for the inconsistent results of RIPC in previous 
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clinical studies. The longer time window of delayed preconditioning may be more beneficial 
in a real clinical setting, such as during long aorta cross clamp durations in complex cardiac 
surgeries in which peri-operative ischaemic insults do not always occur within 2-3 h after 
preconditioning. 
This study had several limitations. First, study was not powered to detect AKI or 
composite outcomes, and the results should be interpreted with caution. Second, confounders 
such as patient age, sex, comorbidities, and drugs may have affected the study outcomes. In 
this study, patients with diabetes were excluded since release of a humoral cardioprotective 
factor is attenuated in diabetic patients.[28] Beta blockers are known to inhibit 
preconditioning pathways;[28] however, use of beta blockers were comparable between 
groups. Third, the choice of anaesthetics can be a major confounder in surgical settings. We 
avoided volatile anaesthetics because inherent preconditioning might be fully exploited by a 
volatile anaesthetic itself.[29] Kottenberg et al. reported that propofol may interfere with the 
cardioprotective effects of RIPC.[30] However, several studies reported a significant decrease 
in myocardial injury following RIPC under propofol anaesthesia.[5, 9, 15] Thus, more 
evidence is needed to clarify the effects of propofol on RIPC effects. Moreover, larger 
multicenter randomized clinical trials are required to fully elucidate the effects of delayed 
RIPC on clinical outcomes.  
In summary, delayed RIPC did not provide cardioprotective effects in patients 
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Table 1. Baseline characteristics 





Age, years 61.8±11.1 62.8±13.2 0.618 
Male sex, n (%) 39 (48.8) 46 (57.5) 0.267 
Weight, kg 58.0±10.4 59.3±8.9 0.393 
Height, cm 160.0±9.7 162.6±10.0 0.102 
Body mass index, kg/cm2 22.5±3.0 22.4±2.8 0.789 
Hypertension, n (%) 24 (30.0) 31 (38.8) 0.244 
Previous stroke, n (%) 6 (7.5) 8 (10.0) 0.576 
Current smoker, n (%) 13 (16.3) 15 (18.8) 0.677 
Left ventricle ejection fraction, % 59.2±8.9 57.7±9.8 0.335 
Congestive heart failure, n (%) 13 (16.3) 11 (13.8) 0.658 
Previous cardiac surgery, n (%) 21 (26.3) 15 (18.8) 0.256 
EuroSCORE II 2.7±2.6 2.4±1.9 0.458 
Serum troponin I, ng/mL 0.0±0.0 0.8±6.1 0.316 
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Serum creatinine, mg/dL 0.9±0.2 0.9±0.3 0.684 
Serum lactate, mmol/L 1.1±0.4 1.1±0.5 0.490 
Platelet count, x109/L 197.9±57.9 200.0±65.5 0.886 
Fibrinogen, mg/dL 279.0±69.5 296.4±56.1 0.056 
Type of procedures, n (%)    
   Mitral valve (alone) 21 (26.3) 14 (17.5) 0.181 
   Aortic valve (alone) 22 (27.5) 22 (27.5) 1.000 
   Other valve (alone) 4 (5.0) 4 (5.0) 1.000 
   Aorta surgery (alone) 2 (2.5) 4 (5.0) 0.681 
   Other procedures (alone) 4 (5.0) 5 (6.3) 0.732 
   Combined procedures 27 (33.8) 31 (38.8) 0.511 
      Coronary artery bypass graft 5 (6.3) 5 (6.3) 1.000 
Continuous data are reported as means ± SD. RIPC, remote ischaemic preconditioning; 
EuroSCORE II European System for Cardiac Operative Risk Evaluation II. 
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Table 2. Intra-operative characteristics 






Time from RIPC or sham to aorta cross clamp, h 29.5±5.8 29.3±6.9 0.837 
Time from RIPC or sham to reperfusion, h 31.9±5.9 31.8±6.7 0.923 
Aortic cross-clamp duration, min 145.2±59.0 149.2±58.7 0.663 
Cardiopulmonary bypass duration, min 228.4±85.8 233.4±79.2 0.707 
Duration of surgery, min 447.4±142.2 445.7±134.8 0.937 
Data are presented as means ± SD. RIPC, remote ischaemic preconditioning
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Table 3. Clinical outcomes 











Mechanical ventilation time, h 20 (15–46) 20 (16–46)  0.877  NS 
ICU length of stay, day 4 (3–7) 4 (3–8)  0.525  NS 
Hospital length of stay, day 14 (9–20) 14 (10–20)  0.874  NS 
Use of IABP or ECMO, n (%) 8 (10.0) 10 (12.5) 0.800 (0.333–1.922) 0.617 0.800 (0.131–2.875) NS 
Reoperation for bleeding, n (%) 4 (5.0) 6 (7.5) 0.667 (0.196–2.273) 0.514 0.667 (0.086–9.785) NS 
In-hospital mortality, n (%) 2 (2.5) 5 (6.3) 0.400 (0.080–2.002) 0.246 0.400 (0.091–10.001) NS 
Cardiovascular mortality, n (%) 1 (1.3%) 4 (5.0%) 0.250 (0.029–2.188) 0.367 NA NS 
Myocardial infarction, n (%) 0 (0.0) 3 (3.8) NA 0.080 NA NS 
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New-onset atrial fibrillation, n (%) 27 (33.8) 39 (48.8) 0.692 (0.473–1.013) 0.054 0.692 (0.294–1.283) NS 
Ventricular arrhythmia, n (%) 21 (26.3) 21 (26.3) 1.000 (0.595–1.681) 1.000 1.000 (0.393–2.260) NS 
Stroke, n (%) 1 (1.3) 1 (1.3) 1.000 (0.064–15.712) 1.000 NA NS 
Post-operative delirium, n (%) 18 (22.5) 17 (21.3) 1.059 (0.589–1.902) 0.848 1.059 (0.367–3.206) NS 
Acute kidney injury, n (%) 24 (30.0) 38 (47.5) 0.632 (0.421–0.948) 0.023 0.632 (0.338–1.232) 0.46 
AKIN 1, n (%) 15 (18.8) 33 (41.3)     
AKIN 2, n (%) 5 (6.3) 1 (1.3)     
AKIN 3a, n (%) 4 (5.0) 4 (5.0)     
RRT within 48 h, n (%) 2 (2.5) 2 (2.5) 1.000 (0.144–6.926) 1.000 NA NS 
RRT in-hospital, n (%) 6 (7.5) 6 (7.5) 1.000 (0.337–2.969) 1.000 1.000 (0.098–6.701) NS 
Respiratory failure, n (%) 6 (7.5) 10 (12.5) 0.600 (0.229–1.573) 0.292 0.600 (0.076–6.310) NS 
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Persistent cardiogenic shock, n (%) 14 (17.5) 14 (17.5) 1.000 (0.510–1.960) 1.000 1.000 (0.313-3.678) NS 
Gastrointestinal complications, n (%) 2 (2.5) 3 (3.8) 0.667 (0.114–3.883) 0.650 NA NS 
Composite complicationsb, n (%) 52 (65.0) 65 (81.3) 0.800 (0.660–0.970) 0.020 0.800 (0.574-1.091) 0.42 
Continuous data are presented as means ± SD, or median (IQR). aincludes RRT, bComposite complications include in-hospital death, 
myocardial infarction, new onset atrial fibrillation, stroke, acute kidney injury, respiratory failure, and persistent cardiogenic shock, and 
gastrointestinal complication, cAdjusted for multiple comparisons using the Hochberg procedure. NS, adjusted p value>0.999. CI, confidence 
interval; RR, relative risk; RIPC, remote ischaemic preconditioning; ICU, intensive care unit; IABP, intraaortic balloon pump; ECMO, 




Figure 1. Consort diagram. 
Figure 2. Peri-operative concentrations of serum troponin I.  
Data are presented as the median and quartiles. Error bars indicate the 90th and 10th 
percentiles. Asterisks indicate significant changes compared with the pre-operative value 
(*p<0.05). RIPC, remote ischaemic preconditioning. 
Figure 3. Peri-operative concentrations of serum creatinine.  
Data are presented as the median and quartiles. Error bars indicate the 90th and 10th 
percentiles. Asterisks indicate significant changes compared with the pre-operative value 
(*p<0.05). RIPC, remote ischaemic preconditioning; POD, post-operative day. 
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